Repros Therapeutics Inc. (RPRX) Release: FDA Recommends Running Phase 2b Trial of Proellex®-V in the Treatment of Severe Menstrual Bleeding Associated With Uterine Fibroids
5/23/2013 10:02:27 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
THE WOODLANDS, Texas, May 22, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced it has met with the FDA regarding the clinical development of Proellex-V, the vaginally administered product, in the treatment of uterine fibroids. The FDA recommended that a Phase 2b study should be conducted as a prelude to the Phase 3 program. During the meeting, Repros and the FDA agreed that:
Help employers find you! Check out all the jobs and post your resume.
comments powered by